Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta2-agonists: friend or foe?

Jean G Ford1, Javed Iqbal, Yisa Sunmonu

  • 1Bloomberg School of Public Health, Johns Hopkins University, Department of Epidemiology, Baltimore, Maryland 21205, USA. jford@jhsph.edu

Seminars in Respiratory and Critical Care Medicine
|August 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Valorization of algal biomass to synthesize heterogeneous gC<sub>3</sub>N<sub>4</sub>-Biochar photocatalyst for the treatment of industrial wastewater using photocatalysis-persulfate oxidation process.

Chemosphere·2024
Same author

Exploring asymmetric influence of R&D expenditures on CO<sub>2</sub> emissions in China: evidence from nonlinear ARDL model.

Environmental science and pollution research international·2024
Same author

A comparison of continuous cold flow and compression device and traditional icing regimen and no icing following anterior cruciate ligament reconstruction: A pilot study.

JPMA. The Journal of the Pakistan Medical Association·2024
Same author

Role of deep brain stimulation (DBS) in addiction disorders.

Surgical neurology international·2024
Same author

Co-Loading of Black Phosphorus Nanoflakes and Doxorubicin in Lysolipid Temperature-Sensitive Liposomes for Combination Therapy in Prostate Cancer.

International journal of molecular sciences·2024
Same author

The sexually divergent cFos activation map of fear extinction.

Heliyon·2024

Regularly scheduled beta2-agonists for asthma are generally safe and effective. While some studies link their use to increased asthma risks, this review suggests they are beneficial when used appropriately.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Genetics

Background:

  • Controversy exists regarding the safety of regularly scheduled beta2-agonist use in asthma management.
  • Epidemiological and clinical studies have reported associations between regular beta-agonist use and increased asthma morbidity and mortality.
  • Inconsistencies across studies necessitate a thorough review of the evidence.

Purpose of the Study:

  • To review the effects of beta2-agonists on asthma severity.
  • To explore potential mechanisms linking regular beta-agonist use to adverse asthma outcomes.
  • To examine the influence of genetic variations in the beta2-adrenergic receptor on asthma severity.

Main Methods:

  • Literature review of epidemiological and clinical studies on beta2-agonist use in asthma.

Related Experiment Videos

  • Discussion of proposed biological mechanisms for adverse events.
  • Brief review of pharmacogenetic studies concerning beta2-adrenergic receptor polymorphisms.

    • Main Results:

    • Evidence suggests that beta2-agonists, as currently used in the United States, are generally safe and effective for asthma.
    • Potential mechanisms for adverse outcomes are discussed, but overall findings support therapeutic benefit.
    • Genetic diversity at the beta2-adrenergic receptor locus may influence asthma severity and response to treatment.

    Conclusions:

    • The current evidence supports the safety and efficacy of commonly used beta2-agonists in asthma management.
    • While risks have been debated, beta2-agonists are considered beneficial, not detrimental, when used appropriately.
    • Pharmacogenetic factors may play a role in individual responses to beta2-agonist therapy.